The Journal of Immunology, Vol 142, Issue 8 2654-2659, Copyright © 1989 by American Association of Immunologists

ARTICLES

Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6

G Biesecker and CM Gomez
Department of Pathology and Laboratory Medicine, Hahnemann University, Philadelphia, PA 19102-1192.

The role of the lytic complement C5b-9 membrane attack complex (MAC) in acute passive transfer experimental autoimmune myasthenia gravis (EAMG) produced in rats was investigated by in vivo inhibition of MAC formation with anti-C6 Fab. Anti-C6 Fab totally inhibited in vitro serum hemolytic activity, but did not consume or inhibit early complement pathways. Injection of rats with 0.12 mg/ml anti-C6 Fab reduced serum C6 to 8% and inhibited the muscle weakness, electrophysiologic abnormalities and loss of acetylcholine receptor (AChR) associated with acute EAMG. This level of C6 inhibition reduced the total serum complement hemolytic activity to 29% of normal but did not reduce the serum levels of complement components C3, C5, or C7. Treatment of rats with lower amounts of anti-C6 Fab (0.08 mg/ml) also inhibited clinical and electrophysiologic signs of EAMG, however, the lower amount of anti-C6 did not prevent the loss of muscle AChR. Both the higher and the lower amount of anti-C6 Fab inhibited the accumulation of macrophages at muscle motor end-plates. The inhibition by anti-C6 indicates that muscle weakness and electrophysiologic abnormalities associated with EAMG are dependent on the complement MAC, and that muscle weakness results from tissue injury in addition to loss of muscle membrane and AChR.

This article has been cited by other articles:

				Y. Zhou, B. Gong, F. Lin, R. P. Rother, M. E. Medof, and H. J. Kaminski Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis J. Immunol., December 15, 2007; 179(12): 8562 - 8567. [Abstract] [Full Text] [PDF]

				S. T. Spicer, G. T. Tran, M. C. Killingsworth, N. Carter, D. A. Power, K. Paizis, R. Boyd, S. J. Hodgkinson, and B. M. Hall Induction of Passive Heymann Nephritis in Complement Component 6-Deficient PVG Rats J. Immunol., July 1, 2007; 179(1): 172 - 178. [Abstract] [Full Text] [PDF]

				P. S. Bora, J.-H. Sohn, J. M. C. Cruz, P. Jha, H. Nishihori, Y. Wang, S. Kaliappan, H. J. Kaplan, and N. S. Bora Role of Complement and Complement Membrane Attack Complex in Laser-Induced Choroidal Neovascularization J. Immunol., January 1, 2005; 174(1): 491 - 497. [Abstract] [Full Text] [PDF]

				A. Saoudi, I. Bernard, A. Hoedemaekers, B. Cautain, K. Martinez, P. Druet, M. De Baets, and J.-C. Guery Experimental Autoimmune Myasthenia Gravis May Occur in the Context of a Polarized Th1- or Th2-Type Immune Response in Rats J. Immunol., June 15, 1999; 162(12): 7189 - 7197. [Abstract] [Full Text] [PDF]

				B. Balasa, C. Deng, J. Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick Interferon gamma  (IFN-gamma ) Is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental Autoimmune Myasthenia gravis in Mice J. Exp. Med., August 4, 1997; 186(3): 385 - 391. [Abstract] [Full Text] [PDF]

				H. Weisman, T Bartow, M. Leppo, H. Marsh Jr, G. Carson, M. Concino, M. Boyle, K. Roux, M. Weisfeldt, and D. Fearon Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis Science, July 13, 1990; 249(4965): 146 - 151. [Abstract] [PDF]